Citius Oncology is a pharmaceutical company that provides the development and commercialization of innovative oncology therapies.
Citius Oncology has raised $25.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in May 2026.
Citius Oncology's investors include Avenue Capital Group.
Citius Oncology is headquartered in Cranford, United States.
Citius Oncology is a pharmaceutical company that provides the development and commercialization of innovative oncology therapies.
Citius Oncology is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Citius Oncology — Funding & Investors." VCBacked, May 5, 2026, https://www.vcbacked.co/company/citius-oncology. Accessed September 30, 2026.
VCBacked. (2026). Citius Oncology — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/citius-oncology
{{cite web |title=Citius Oncology — Funding & Investors |url=https://www.vcbacked.co/company/citius-oncology |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated